GNMX Shares Outstanding History



Below is a table of the GNMX shares outstanding history going back to 5/11/2011:

Date GNMX Shares Outstanding
5/11/20119.61M
8/5/20119.64M
11/7/20119.72M
2/19/20129.76M
5/11/20129.77M
6/18/20129.77M
8/9/201211.98M
11/11/201212.26M
3/11/201318.00M
5/6/201318.48M
8/4/201318.48M
11/4/201318.49M
2/17/201418.69M
5/7/201418.76M
7/11/201418.81M
10/10/201418.91M
2/9/201524.84M
4/16/201524.90M
8/5/201524.93M
10/15/201532.86M
2/19/201632.92M
5/5/201633.21M
8/1/201637.08M
10/21/201637.08M
10/31/201637.10M
3/3/201737.11M
5/2/201737.11M
8/4/201737.11M
10/26/201759.33M
3/9/201859.34M
5/10/201859.34M
8/1/201859.34M
10/30/201864.77M
3/26/201964.77M
5/9/201964.77M
8/9/201964.77M
11/11/201964.77M

Also see: GNMX Market Cap History
GNMX YTD Return
GNMX Historical Shares Outstanding:
+25.13% CAGR
GNMX Historical Shares Outstanding: +25.13% CAGR

Mouse over chart for data details
5/11/2011 ...11/11/2019
Aevi Genomic Medicine is a clinical stage biopharmaceutical company with a focus on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated therapies for pediatric onset, life-altering diseases, including rare and orphan diseases. Co.'s product pipeline includes: AEVI-002, which is an anti-LIGHT monoclonal antibody that is in development for use in Pediatric Onset Crohn's disease; and AEVI-005, which is the monoclonal antibody Co. is developing as part of its ongoing collaboration with Kyowa Hakko Kirin Co., Ltd. whereby Co. is studying it in an undisclosed ultra-orphan auto-immune pediatric disease. We show 37 historical shares outstanding datapoints in our coverage of GNMX's shares outstanding history.

Understanding the changing numbers of GNMX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like GNMX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching GNMX by allowing them to research GNMX shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree GNMX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Aevi Genomic Medicine (GNMX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

GNPX Shares Outstanding History
GOSS Shares Outstanding History
GOVX Shares Outstanding History
GRAY Shares Outstanding History
GRI Shares Outstanding History
GRPH Shares Outstanding History
GRTS Shares Outstanding History
GRTX Shares Outstanding History
GTBP Shares Outstanding History
GTHX Shares Outstanding History
More Healthcare companies »

 

GNMX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.